Clinical data presented during the annual EuroPCR demonstrated positive long-term performance and durability for the CoreValve transcatheter aortic valve replacement system from Medtronic, Inc. (NYSE: MDT). Two-year results from the pivotal 18-French CoreValve multicentre prospective study provide important additional evidence supporting wider use of the world’s market-leading transcatheter aortic valve.
The CoreValve system received CE (Conformité Européenne) Mark in March 2007. It is not yet available in the United States for clinical trial or commercial sale or use. The CoreValve system, designed to replace a diseased aortic valve without open-heart surgery or surgical removal of the native valve, has now been implanted in more than 10,000 patients worldwide in 32 countries outside the United States. Typically delivered through the femoral artery, CoreValve is used in 75 percent of transarterial transcatheter valve replacement procedures.